Immunotherapy of cancer
Invited discussant abstracts 1052PD, 1053PD, 1054PD and 1056PD
Date
10 Oct 2016Session
Immunotherapy of cancerPresenters
Suzy SchollAuthors
S. SchollAuthor affiliations
- Oncology, Institut Curie, 75005 - Paris/FR
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
1903 - The MITCI (phase 1b) study: a novel immunotherapy combination of coxsackievirus A21 and ipilimumab in patients with advanced melanoma
Presenter: Brendan Curti
Session: Immunotherapy of cancer
Resources:
Abstract
1584 - Preventive dendritic cell vaccination in healthy Lynch syndrome mutation carriers
Presenter: Harm Westdorp
Session: Immunotherapy of cancer
Resources:
Abstract
3680 - Phase I/II CANON study: oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21
Presenter: Hardev Pandha
Session: Immunotherapy of cancer
Resources:
Abstract
1650 - Phase 1 study of MEDI0562, a humanized OX40 agonist monoclonal antibody (mAb), in adult patients (pts) with advanced solid tumors
Presenter: Bonnie Glisson
Session: Immunotherapy of cancer
Resources:
Abstract
3047 - Ongoing complete remissions in phase 1 of ZUMA-1: a phase 1-2 multi-center study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in patients with refractory aggressive B cell non-Hodgkin lymphoma (NHL)
Presenter: Frederick Locke
Session: Immunotherapy of cancer
Resources:
Abstract
Slides
Invited discussant abstracts 1049PD, 1050PD, 1051PD and LBA38
Presenter: Thomas Powles
Session: Immunotherapy of cancer
Resources:
Slides
Webcast
Invited discussant abstracts 1047O and 1048O
Presenter: Inge-Marie Svane
Session: Immunotherapy of cancer
Resources:
Slides
2428 - Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P)
Presenter: Roy Herbst
Session: Immunotherapy of cancer
Resources:
Abstract
2130 - Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: A phase 1, open-label study in advanced malignancies
Presenter: Omid Hamid
Session: Immunotherapy of cancer
Resources:
Abstract
3042 - Changes in serum IL8 levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients
Presenter: Miguel Sanmamed
Session: Immunotherapy of cancer
Resources:
Abstract
Slides
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.